Form D · Pharmaceuticals

ImmunoPrecise Antibodies Ltd.

Victoria, A1 · CIK 0001715925

Offering snapshot reported Jul 30, 2024 · SEC filing

Reported sold
$2M
Offering amount: $3M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 16, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 30, 2024Initial$2,000,000No comparison1SEC filing
Oct 9, 2018Initial$341,710No comparison5SEC filing
Jul 9, 2018Initial$7,571No comparison1SEC filing
Aug 31, 2017Initial$133,875No comparison7SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$210K
Finders' fees
$0
Form D file number
021-520087

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Clear Street LLC288933

Source: Form D, filed Jul 30, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jennifer Bath Director, Executive
Robert Beecroft Director, Executive
Robert Burke Director
Chris Buyse Director
Guy Champagne Director
Thomas D'orazio Director, Executive
James Kuo Director
Mitch Levine Director
Ilse Roodnik Executive
Greg Smith Director
Barry Springer Director
Kristin Taylor Executive
Natasha Tsai Executive
Dawn Wattie Executive
Dirk Witters Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
3204 4464 Markham Street
Victoria, A1, V8Z 7X8